Flocet IV Infusion

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Flocet IV Infusion 200 mg/100 ml is an antibacterial agent used for the treatment of bacterial infections in many parts of the body, including the respiratory tract, kidney, skin, soft tissue, and urinary tract.

For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.

• Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)
• Acute Otitis Media
• Bacterial Infections
• Cervicitis
• Community Acquired Pneumonia (CAP)
• Complicated Urinary Tract Infection
• Conjunctivitis
• Epididymitis
• Hansen's Disease
• Nongonococcal urethritis
• Otitis Externa
• Prostatitis
• Skin and Subcutaneous Tissue Bacterial Infections
• Spontaneous Bacterial Peritonitis (SBP)
• Traveler's Diarrhea
• Ulcerative keratitis
• Acute Pelvic inflammatory disease
• Acute
• uncomplicated Gonorrhea
• Chronic suppurative Otitis media
• Uncomplicated Cystitis

Flocet IV Infusion 200 mg/100 ml is a quinolone/fluoroquinolone antibiotic. Flocet IV Infusion 200 mg/100 ml is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Flocet IV Infusion 200 mg/100 ml is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Flocet IV Infusion 200 mg/100 ml acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.

Bioavailability of ofloxacin in the tablet formulation is approximately 98%

32%

Flocet IV Infusion 200 mg/100 ml is mainly eliminated by renal excretion, where between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via urine within 48 hours of dosing. About 4-8% of an ofloxacin dose is excreted in the feces and the drug is minimally subject to biliary excretion.

9 hours

LD₅₀=5450 mg/kg (orally in mice)

• Limit caffeine intake.
• Take with or without food. The absorption is unaffected by food.

• Enteric fever: For adults 200 mg, every 12 hours, for 5 days. For children 15 mg/kg/day in 2 divided doses for 3 days.
• Shigellosis: 400 mg single dose.
• Multi-drug-resistant tuberculosis: 400 mg twice daily along with conventional  anti-tuberculosis drugs.
• Lower respiratory tract infection: 400 mg daily, increasing, if necessary, to 400 mg twice daily.
• Uncomplicated Urinary Tract Infections: A single dose of 200/400 mg.
• Uncomplicated urethral and cervical gonorrhoea: A single dose of 400 mg.
• Non-gonococcal urethral and cervicitis: 400 mg daily in single or divided doses.
• Complicated Urinary Tract Infection: 200/400 mg/day for 7 days.
• Impaired liver function: The excretion of ofloxacin may be reduced inpatients with severe hepatic dysfunction.
• Children: Flocet IV Infusion 200 mg/100 ml is usually not indicated for use in children or growing adolescents.
• Elderly: No adjustment of dosage is required in the elderly.

• Eye: Instill 1 drop in the affected eye(s) every 2 to 4 hours for the first two days and then 4 times daily. The length of treatment should not exceed ten days.
• Ear: Instill 1-2 drops in the affected ear(s) twice daily or as needed.